Can Targeted Radiation Change the Future of Brain Cancer? | Dr. Marc Hedrick | Plus Therapeutics

Send us Fan MailIn this episode of Rare Connection, host Joanna Ball speaks with Dr. Marc Hedrick, President and CEO of Plus Therapeutics, about emerging technologies aimed at improving outcomes for patients with some of the most difficult-to-treat cancers affecting the central nervous system.Dr. Hedrick discusses leptomeningeal metastases (LM), a serious condition that occurs when cancer spreads to the membranes and fluid surrounding the brain and spinal cord, as well as recurrent glioblastoma, one of the most aggressive forms of brain cancer.The conversation explores the challenges of diagnosing central nervous system cancers, the role of advanced diagnostic tools like the CNSide® CSF Assay Platform, and how targeted radiotherapeutics may help deliver treatment directly to affected areas while limiting exposure to healthy tissue.Topics covered include:• What leptomeningeal metastases are and why they are so difficult to diagnose • Current treatment challenges for LM and glioblastoma patients • The CNSide® diagnostic platform and cerebrospinal fluid testing • How radiotherapeutics differ from traditional radiation therapy • Targeted drug delivery to the central nervous system • Clinical trials and emerging research in neuro-oncology • The future of precision medicine for brain and spinal cancersWhether you're a patient, caregiver, healthcare professional, researcher, or advocate, this episode provides insight into innovative approaches that may help transform the diagnosis and treatment of cancers that spread to the central nervous system.To learn more about Plus Therapeutics and ongoing clinical research, visit https://plustherapeutics.comSupport the showSubscribe to Rare Connection and Rare Chef, leave a review, and share this episode to help us connect patients, families, advocates, researchers, and medical professionals around the world.Support the show